Advertisement News Archives - Page 1447 of 5234 - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

News

August 26, 2026

Jazz secures FDA approval for Ziihera in advanced HER2+ GEA

The US Food and Drug Administration (FDA) has approved two Jazz Pharmaceuticals regimens containing Ziihera (zanidatamab-hrii) for the first-line treatment of adults with unresectable, locally advanced or metastatic human epidermal growth factor receptor 2 (HER2)-positive gastroesophageal adenocarcinoma (GEA).

Jazz secures FDA approval for Ziihera in advanced HER2+ GEA